Guaranteed Purchase Of All Doses Could Attract Flu Vaccine Makers, Wyeth Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Guaranteeing that all flu vaccine doses produced will be purchased is the most significant way Congress can create incentives for manufacturers to re-enter the flu vaccine market, Wyeth VP-Scientific Affairs Peter Paradiso, PhD, said Nov. 16
You may also be interested in...
3.5 Mil. Doses Of Sanofi-Aventis’ Fluzone Still Unused, CDC Says
HHS will wait to distribute GSK’s Fluarix until Fluzone supply is exhausted, Centers for Disease Control & Prevention Director Gerberding says. Some states have begun to relax recommendations so that people who are not in high priority groups can get vaccinated.
3.5 Mil. Doses Of Sanofi-Aventis’ Fluzone Still Unused, CDC Says
HHS will wait to distribute GSK’s Fluarix until Fluzone supply is exhausted, Centers for Disease Control & Prevention Director Gerberding says. Some states have begun to relax recommendations so that people who are not in high priority groups can get vaccinated.
FluMist May Require Additional Phase III Trial To Expand Patient Population
MedImmune seeks to expand the indication for its intranasal flu vaccine to people ages 50 to 64; the company is waiting to see if FDA will accept new analyses of existing data in the target age group. MedImmune and Chiron suggest incentives to increase flu vaccine demand during a House committee hearing.